SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Sandro Anchisi, Marc Küng et al.|BMC Cancer|2016Cited by 46
Neoadjuvant radiotherapy combined with capecitabine and sorafenib in patients with advanced KRAS -mutated rectal cancer: A phase I/II trial (SAKK 41/08)Roger von Moos, Kathrin Zaugg, Dieter Koeberle et al.|European Journal of Cancer|2017Cited by 27
Additional file 1: Table S1. of SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Ralph C. Winterhalder, Martin Bigler et al.|Figshare|2016Cited by 0
Additional file 1: Table S1. of SAKK 24/09: safety and tolerability of bevacizumab plus paclitaxel vs. bevacizumab plus metronomic cyclophosphamide and capecitabine as first-line therapy in patients with HER2-negative advanced stage breast cancer - a multicenter, randomized phase III trialChristoph Rochlitz, Ralph C. Winterhalder, Richard Cathomas et al.|Figshare|2016Cited by 0